Bionomics Limited
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Spyridon Papapetropoulos
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Greenhill Road Eastwood SA Australia 5063
- IPO Date
- Jun 24, 2014
- Website
- bionomics.com.au
- Similar Companies
- Business
- Bionomics Limited (BNOEF) is a clinical-stage biopharmaceutical company that discovers and develops novel, first-in-class allosteric ion channel modulators, including proprietary negative allosteric modulators (NAMs) of the α7 nicotinic acetylcholine receptor, for the treatment of serious central nervous system (CNS) disorders such as social anxiety disorder (SAD) and post-traumatic stress disorder (PTSD); its lead product candidate BNC210, an oral small molecule with non-sedating, non-habit forming anxiolytic and antidepressant properties, advances in Phase 3 clinical trials for SAD via the AFFIRM-1 study and prepares for Phase 3 initiation in PTSD, while the preclinical pipeline features α7 receptor positive allosteric modulators (PAMs) like BNC375 for cognitive impairment in Alzheimer's disease partnered with Merck Sharpe & Dohme (MSD), Kv3.1/3.2 and Nav1.7/1.8 ion channel modulators seeking strategic partners, and legacy oncology assets including BNC101, a monoclonal antibody targeting cancer stem cell antigen LGR5 exclusively licensed to Carina Biotech for CAR-T therapy development, and BNC105, a vascular disrupting agent for solid tumors. Founded in 1996 and headquartered in Adelaide, South Australia, the company operates primarily in Australia, the United States, and France, targeting patients with high unmet needs in CNS and oncology segments through its expertise in ion channel biology, genomics platforms like Angene and MultiCore, and translational medicine. Recent developments include a milestone payment of A$1 million received from Carina Biotech in 2024 under the BNC101 license potentially worth up to A$118 million plus royalties, initiation of the AFFIRM-1 Phase 3 trial for BNC210 in SAD following a successful End-of-Phase 2 FDA meeting in June 2024 with Phase 3 PTSD trial startup targeted for late 2025, extension of BNC210 intellectual property beyond 2040, a strategic partnership with MSD generating US$30 million in upfront and Phase 1 milestone payments with up to US$465 million more possible, securing up to $70 million in funding via private placement and ATM facilities to support operations into Q3 2025, and a completed re-domiciliation to the United States as Neuphoria Therapeutics Inc. in late 2024 enabling Nasdaq trading under NEUP while delisting from the ASX, alongside cost-cutting measures and U.S. management strengthening.
Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation
Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting
Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement
Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program
Bionomics to Present at the ThinkEquity Conference
Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
Bionomics Limited announces intention to re-domicile to the United States
Bionomics shares soar almost 400% after positive phase IIb results from PTSD treatment
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial
Bionomics Announces Plans to Conduct U.S. Initial Public Offering
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD